Page 146 - CW E-Magazine (5-9-2023)
P. 146

Top Stories                                                                                                                                                                    Pharmaceuticals


       ZINC METAL                                                                                                    FUTURE PLANS

       Hindustan Zinc plans to ramp up capacity by 50%                                                               Sun Pharma expects Taro buyout to aid dermatology

          Vedanta-owned Hindustan Zinc Ltd.  in latest technology for maximum metal  employees, including 109 women   business profi tability
       (HZL) plans to raise  its zinc pro-  recovery and digitisation of mining &  engineers, who are breaking the glass
       duction capacity from 1-mtpa to 1.5-mtpa  smelting operations.     ceiling in mining and smelting opera-         Sun Pharma is looking to fully ac-  constant,  increasing  competition pres-  had noted. Sun Pharma had acquired a
       through   brownfi eld   expansion.                                  tions. At HZL, women are working in all    quire its Israel-based unit Taro Pharma-  sure,” Mr. Shanghvi said in an analyst  controlling stake in Taro in September
       “Zinc  will  play a key role in India’s   “Today, the Pantnagar Metal Plant is  key functions right from driving large   ceutical Industries in order to integrate  call.  “And as a stand-alone  company,  2010 after nearly four  years of legal
       growth story. We are looking forward to  powered entirely by renewable energy,  mining vehicles to operating plants and   the dermatology business with itself and  it will be very diffi cult for Taro as an  wrangling.
       at least 3-4% growth in the sector and  and with our solar and wind projects  working night-shifts, she said. Currently,   keep it profi table amid increasing com-  independent company  to  continue to
       plan to ramp up our production by 50%  accounting for 180-MW and 250-MW  19.5% of executive workforce, 35% of   petition in the segment, according to  operate that business profi tably. So that  R&D spending
       from 1-mtpa to 1.5-mtpa,” said Ms. Priya  respectively, HZL will reduce its coal  management committee and 21% of   Managing Director, Mr. Dilip Shanghvi.  broadly is the reason why we felt that   Meanwhile, speaking at the company’s
       Agarwal Hebbar, Chairperson, HZL,  dependency by 50% by 2025,” she said.  executive committee comprise women,                                   it’s useful for us to consider integrating  Annual General  Meeting (AGM),
       at  the company’s 57th annual  general                             she added.In Q1 FY24, HZL’s net profi t        Sun Pharma has proposed to fully  that with Sun Pharma,” he added.  Mr. Shanghvi said the company aims to
       meeting.                            HZL was the fi rst in the country to  dropped 36% to Rs. 1,964-crore, against   acquire Taro through a reverse triangu-                        spend 7-8% of sales in the current fi scal
                                         introduce battery-operated electric vehi-  Rs. 3,092-crore during the correspond-  lar merger. The company has issued a   The purchase price offered by Sun  on research and development as it looks
          During  FY23,   the  company   cles in underground mining, and is aim-  ing quarter of last year, while revenue   letter to the Taro board with a proposal  represents a premium  of 31.2% over  to further strengthen its product port-
       achieved refi ned metal production ex-  ing to achieve its ESG targets by 2030,  dropped 22% to Rs. 7,282-crore (Rs.   containing a non-binding indication of  Taro’s closing price on May 25, 2023,  folio across therapeutic segments. The
       ceeding 1-mt, and in Q1FY24 it recor-  ahead of the parent Vedanta Group’s goal  387-crore), due to lower prices in the   interest to acquire all of the outstand-  a 41.5% premium over Taro’s average  drug major spent about Rs. 2,400-crore
       ded a production of 257-kt by investing  set at 2050. The company has 505 women  recent quarter.              ing ordinary shares for a purchase price  closing price in the last 60 days and a  on R&D in 2022-23, which accounted
       COMMITMENT TO SUSTAINABILITY                                                                                  of $38 per ordinary share in cash. Sun  compelling liquidity opportunity for  for 5.5% of sales. Mr. Shanghvi said
                                                                                                                     Pharma currently owns  around 78%  Taro’s shareholders, Sun Pharma had  the expansion of its global  speciality
       Grolman Group receives Ecovadis Platinum                                                                      stake in Taro.                    stated in a regulatory fi ling in May this  business is expected to continue going
                                                                                                                                                       year.  Under the indicative proposal,  ahead.   “All our  businesses  are well-
          The Grolman Group, an  inter-  refl ecting its commitment to sustainable  ted to this milestone,” said Mr. Florian   “My own assessment is that the derma-  post the acquisition, Taro will become a  positioned, and we expect high-single-
       national specialty chemical ingredients  practises. “The path to this remarkable  Grolman, CEO, Grolman Group.   tology business,  which is  the primary  wholly-owned subsidiary of Sun Pharma  digit consolidated  topline  growth
       distribution  fi rm,  with  sales  offi ces  achievement was marked by conscien-                                focus for  Taro, is a business under  and will be delisted from NYSE,  it  for FY24,” he added.
       based in all European countries, Turkey,  tious efforts. From transparent reporting   The  Grolman  Group, run by the
       Maghreb, Egypt, India and China, has  to active stakeholder engagement to im-  fi fth generation of the Grolman family,   LOBBYING EFFECT
       announced that it has been awarded  plementing sustainable practises in the  has been privately owned since it was
       a ‘Platinum Rating’ from EcoVadis,  supply chain, every step has contribu-  established in 1855.              NMC puts on hold regulation mandating prescription of
       ACCIDENT
                                                                                                                     generics
       Bromine leakage at PI Industries’ Jambusar plant                                                                 The National Medical Commission  Association (IMA) and Indian Pharma-  Indian Medical Council (Professional
          At least 27 persons were hospita-  offi cials, the incident took place due to  the leakage.  The situation was con-  (NMC) has put on hold regulations  ceutical Alliance  (IPA) had  expressed  Conduct, Etiquette and Ethics) Regula-
       lised after inhaling bromine, a toxic gas,  technical fault in the bromine storage  trolled in an hour. As a precaution, the   that would have made it mandatory for  concern claiming the regulations were  tions, 2002, will come into immediate
       that leaked from the factory of PI Indus-  tank. “This resulted in leakage of red  workers who were working in the   doctors to prescribe generic drugs.  not feasible because of the uncertainty  effect. According to the regulations, regi-
       tries Ltd. near Jambusar in Bharuch dis-  gas in the air. Company’s safety team  affected area were shifted to the hospital                     about their quality. Members of the  stered  medical practitioners and their
       trict of Gujarat. According to company  promptly reached the spot and repaired  and they are safe,” the statement added.   The Registered Medical Practitioner  two associations met the Union Health  families must not receive any gifts, travel
                                                                                                                     (Professional Conduct)  Regulations,  Minister, Dr. Mansukh  Mandaviya,  to  facilities, hospitality, cash or monetary
       Shell India appoints Mansi Madan Tripathy as new                                                              2023, were published  on August 2. It  get their concerns heard.    grants, consultancy fees or honorariums,
                                                                                                                     stated that all doctors must prescribe                              or access to entertainment or recreation
       Country Chair                                                                                                 generic drugs, failing which they will   “It  is  clarifi ed  that  the  National  from pharmaceutical companies or their
                                                                                                                     be penalised, and even their license to  Medical Commission Registered Medi-  representatives, commercial healthcare
          Shell India has announced the  said in a statement. “As Country Chair  her home city, to take up the role,”’ it   practice  may also be suspended for a  cal Practitioner (Professional Conduct)  establishments, medical device compa-
       appointment  of Ms. Mansi Madan  of Shell India, Mansi will oversee Shell  said. A graduate from the National Ins-  period.  It also asked doctors to avoid  Regulations, 2023, shall not be operative  nies, or corporate hospitals “under any
       Tripathy as the new Country Chair,  Group of companies in India, in addi-  titute  of Technology  Kurukshetra,   prescribing branded generic drugs.  and effective till further Gazette Notifi -  pretext”. This does not include salaries
       effective  October 1. She will succeed  tion to her role as Vice President, Shell  Ms. Tripaty has an MBA in Marketing                          cation on the subject by the National  and  benefi ts  that  registered  medical
       Mr. Nitin Prasad who has been the  Lubricants for Asia Pacifi c. Mansi will  from SP Jain Institute of Management   ‘Not sure of quality’        Medical  Commission,”  a  NMC  notifi -  practitioners may receive as employees
       Country Chair since 2016, the company  relocate from Singapore to New Delhi,  and Research.                      Incidentally, the Indian Medical  cation said. However, it added that the  of these organisations.


       146                                                                 Chemical Weekly  September 5, 2023        Chemical Weekly  September 5, 2023                                                              147


                                      Contents    Index to Advertisers    Index to Products Advertised
   141   142   143   144   145   146   147   148   149   150   151